Antidepressant Bone Loss Could Be Prevented with Beta-Blockers
Columbia study in mice reveals how SSRIs reduce bone density and what can be done to stop it
The antidepressant fluoxetine causes bone loss by instructing the brain to send out signals that increase bone breakdown, but a beta-blocker can intercept the signals, a new study in mice has found.
The study was published Sept. 5 in Nature Medicine.
The use of selective serotonin-reuptake inhibitors (SSRIs), a class of drugs broadly prescribed for mood disorders as well as for nonpsychiatric conditions, previously has been associated with an increased risk of bone fracture.
The new study—by Patricia Ducy, PhD, associate professor of pathology & cell biology, and colleagues at Columbia University Medical Center—revealed that fluoxetine, one of the most-prescribed SSRIs, acts on bone physiology through two distinct mechanisms. Initially, fluoxetine protects bone by inhibiting the cells in the skeleton (osteoclasts) that constantly break down and resorb bone. But after a few weeks of treatment, fluoxetine triggers a brain-mediated signal that not only counteracts this effect but also impairs bone formation, thus leading to bone loss.
The brain signals cause bone loss by increasing the amount of epinephrine in the bloodstream, and the researchers found that they could neutralize these signals by co-treating the mice with a low dose of the beta-blocker propranolol. In these animals, bone loss was no longer observed with long-term fluoxetine treatment. The behavior of the mice did not change with co-treatment, suggesting that fluoxetine’s effect on the brain and mood was not impaired.
Adding low-dose propranolol to depression treatment could potentially block an SSRI’s deleterious effect on bone mass, Dr. Ducy says, and may be particularly important for peri- and postmenopausal women since they are already at risk of developing osteoporosis.
The study, titled “Serotonin-reuptake inhibitors act centrally to cause bone loss in mice by counteracting a local anti-resorptive effect,” was published Sept. 5 in Nature Medicine. The authors are María José Ortuño, Samuel T. Robinson, Prakash Subramanyam, Riccardo Paone, Yung-yu Huang, X. Edward Guo, Henry M. Colecraft, J. John Mann, and Patricia Ducy.
The authors declare no competing financial interests.
The study was supported by the NIH (P01 AG032959)